Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ACLY | P53396 | 3/20 | 0.34 |
| ▸ | CFD | P00746 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16005151 | 0.90 | ACLY (0.36) | TSPOKDM4EACLYKMT2AHSD17B10 | |
| SCHEMBL16005607 | 0.86 | KDM4E (0.42) | TSPOKDM4EHSD17B10LMNAHPGD | |
| SCHEMBL16005814 | 0.81 | KDM4E (0.46) | KDM4EACLYCFDHSD17B10LMNA | |
| SCHEMBL16005003 | 0.79 | EGFR (0.44) | KDM4EKMT2AHSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL16005130 | 0.71 | MAPT (0.47) | KDM4EKMT2ALMNAALDH1A1 | |
| SCHEMBL16005243 | 0.68 | CA12 (0.48) | KDM4EKMT2ALMNACYP2C9HPGD | |
| SCHEMBL3489830 | 0.66 | GAA (0.42) | KDM4EACLYLMNAHPGDALDH1A1 | |
| SCHEMBL31343490 | 0.66 | CFD (0.48) | KDM4ECFDKMT2AHSD17B10LMNA | |
| SCHEMBL8003987 | 0.66 | CFD (0.48) | KDM4ECFDKMT2AHSD17B10LMNA | |
| SCHEMBL7952926 | 0.65 | KDM4E (0.70) | KDM4EKMT2AHSD17B10LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | claimed |
| EP-2774914-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Nanjing Medical University (CN) | 2014-09-10 | — | — | EP | claimed |
| EP-2774914-B1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | UNIV NANJING MEDICAL (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-9481636-B2 | N-benzylaniline derivative and uses thereof | NANJING MEDICAL UNIVERSITY (CN) | 2016-11-01 | — | — | US | disclosed |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2774914-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Nanjing Medical University (CN) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | NLN, INA, TRPV1 | TSPO 550/4885KDM4E 2946/4885ACLY 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.